Early trial tests novel cancer vaccine injection
NCT ID NCT05492682
Summary
This early-stage study is testing the safety of a new experimental cancer vaccine called PeptiCRAd-1 when given alongside the immunotherapy drug pembrolizumab. The trial involves 15 adults with various advanced solid tumors that have specific markers. Researchers will inject the vaccine directly into tumors to see if it safely activates the immune system against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Krankenhaus Nordwest
Frankfurt, Germany
-
National Center for Tumor Diseases
Heidelberg, Germany
-
Universitätsklinikum Tübingen
Tübingen, Germany
Conditions
Explore the condition pages connected to this study.